A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
Abstract Camostat mesylate, an oral serine protease inhibitor, is used to treat chronic pancreatitis and reflux esophagitis. Recently, camostat mesylate and its active metabolite 4‐(4‐guanidinobenzoyloxy)phenylacetic acid (GBPA) were reported to inhibit the infection of cells by severe acute respira...
Saved in:
Main Authors: | Junsaku Kitagawa (Author), Hayato Arai (Author), Hiroyuki Iida (Author), Jiro Mukai (Author), Kenji Furukawa (Author), Seitaro Ohtsu (Author), Susumu Nakade (Author), Tomohiro Hikima (Author), Miwa Haranaka (Author), Naoto Uemura (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19
by: Tanuj Sharma, et al.
Published: (2022) -
Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
by: Gwanyoung Kim, et al.
Published: (2023) -
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
by: M. Karolyi, et al.
Published: (2022) -
Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
by: Akmaral Assylbekova, et al.
Published: (2022) -
Profiling ACE2 and TMPRSS2 expression in sinonasal mucosa
by: Michael E Price, et al.
Published: (2022)